Search research articles
Contact Us
Filters
Showing results (81-90 of 103) with videos related to
Page
of 11
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)
|
September 2, 2021
Layilin Anchors Regulatory T Cells in Skin
Pooja Mehta, Victoire Gouirand, Devi P Boda, et al.
Research Square
|
December 11, 2023
The therapeutically actionable long non-coding RNA '<i>T-RECS</i>' is essential to cancer cells' survival in NRAS/MAPK-driven melanoma
Valentin Feichtenschlager, Linan Chen, Yixuan James Zheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 25, 2018
Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab
Richard W Joseph, Jeroen Elassaiss-Schaap, Richard Kefford, et al.
Lancet (London, England)
|
July 19, 2014
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Caroline Robert, Antoni Ribas, Jedd D Wolchok, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 27, 2016
Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib
Georgina V Long, Jeffrey S Weber, Jeffrey R Infante, et al.
The New England Journal of Medicine
|
June 4, 2013
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma
Omid Hamid, Caroline Robert, Adil Daud, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 22, 2023
Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in <i>NRAS</i>-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study
Filippo de Braud, Christophe Dooms, Rebecca S Heist, et al.
Immunity
|
February 10, 2019
Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade
Chien-Chun Steven Pai, John T Huang, Xiaoqing Lu, et al.
JCI Insight
|
December 20, 2019
Regulatory T cells use arginase 2 to enhance their metabolic fitness in tissues
Margaret M Lowe, Ian Boothby, Sean Clancy, et al.
JAMA
|
April 20, 2016
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
Antoni Ribas, Omid Hamid, Adil Daud, et al.
Page
of 11
Search research articles
Search
Showing results (81-90 of 103) with videos related to
Sort By:
Page
of 11
Journal of Immunology (Baltimore, Md. : 1950)
|
September 2, 2021
Layilin Anchors Regulatory T Cells in Skin
Pooja Mehta, Victoire Gouirand, Devi P Boda, et al.
Research Square
|
December 11, 2023
The therapeutically actionable long non-coding RNA '<i>T-RECS</i>' is essential to cancer cells' survival in NRAS/MAPK-driven melanoma
Valentin Feichtenschlager, Linan Chen, Yixuan James Zheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 25, 2018
Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab
Richard W Joseph, Jeroen Elassaiss-Schaap, Richard Kefford, et al.
Lancet (London, England)
|
July 19, 2014
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Caroline Robert, Antoni Ribas, Jedd D Wolchok, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 27, 2016
Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib
Georgina V Long, Jeffrey S Weber, Jeffrey R Infante, et al.
The New England Journal of Medicine
|
June 4, 2013
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma
Omid Hamid, Caroline Robert, Adil Daud, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 22, 2023
Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in <i>NRAS</i>-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study
Filippo de Braud, Christophe Dooms, Rebecca S Heist, et al.
Immunity
|
February 10, 2019
Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade
Chien-Chun Steven Pai, John T Huang, Xiaoqing Lu, et al.
JCI Insight
|
December 20, 2019
Regulatory T cells use arginase 2 to enhance their metabolic fitness in tissues
Margaret M Lowe, Ian Boothby, Sean Clancy, et al.
JAMA
|
April 20, 2016
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
Antoni Ribas, Omid Hamid, Adil Daud, et al.
Page
of 11